In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
Open accessAbstract
In vivo studies have described the pharmacodynamic (PD) characteristics of several triazoles. These investigations have demonstrated that the 24-h area under the concentration-time curve (AUC)/MIC ratio is the critical pharmacokinetic (PK)-PD parameter associated with treatment efficacy. Further analyses from these in vivo studies have demonstrated that a triazole free drug 24-h AUC/MIC of 20 to 25 is predictive of treatment success. We used a neutropenic murine model of disseminated Candida albicans infection to similarly characterize the PK-PD of the new triazole voriconazole. PK and PD parameters (percentage of time that the concentration remains above the MIC [ T > MIC], AUC/MIC ratio, and peak level in serum/MIC ratio) were correlated with in vivo efficacy, as measured by the organism number in kidney cultures after 24 h of therapy. Voriconazole kinetics and protein binding were studied in infected neutropenic mice. Peak level/dose and AUC/dose values ranged from 0.1 to 0.2 and 0.1 to 0.7, respectively. The serum elimination half-life ranged from 0.7 to 2.9 h. The level of protein binding in mouse serum was 78%. Treatment efficacy with the four dosing intervals studied was similar, supporting the AUC/MIC ratio as the PK-PD parameter predictive of efficacy. Nonlinear regression analysis also suggested that the AUC/MIC ratio was strongly predictive of treatment outcomes ( R 2 for AUC/MIC ratio = 82%, R 2 for peak level/MIC ratio = 63%, R 2 for T > MIC = 75%). Similar studies were conducted with nine additional C. albicans isolates with various voriconazole susceptibilities (MICs, 0.007 to 0.25 μg/ml) to determine if a similar 24-h AUC/MIC ratio was associated with efficacy. The voriconazole free drug AUC/MIC ratios were similar for all of the organisms studied (range, 11 to 58; mean ± standard deviation, 24 ± 17 [ P = 0.45]). These AUC/MIC ratios observed for free drug are similar to those observed for other triazoles in this model.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In vivo studies have revealed prolonged periods of growth suppression after triazole concentrations decrease to less than the MIC (long PAFE).
“In addition, in vivo studies have revealed prolonged periods of growth suppression after triazole concentrations decrease to less than the MIC (long PAFE).”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [139]
In vivo animal studies against Candida strains with widely varying MICs show that the 24-hour AUC/MIC target associated with 50% maximal effect for triazoles is near 25 when free drug levels are considered.
“In vivo animal studies against a large number of Candida strains with widely varying MICs (more than 2000-fold) show that the 24-hour AUC/MIC target associated with efficacy (50% maximal effect) for triazoles occurs at a value near 25 when free drug (non-protein bound) levels are considered.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 25 · Cited by 231
Research works printed but not linked: 2
- [4]Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12. [DOI] [PubMed] [Google Scholar]
- [8]Kunin, C. M. 1965. The importance of serum protein binding in determining antimicrobial activity and concentration in serum. Clin. Pharmacol. Ther. 7:168-179. [DOI] [PubMed] [Google Scholar]
- Authors
- Andes, D., Marchillo, K., Stamstad, T., & Conklin, R.
- Affiliations
- University of Wisconsin System (US)
- William S. Middleton Memorial Veterans Hospital (US)
- ORCID
- Andes, D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-10
- Volume
- 47
- Issue
- 10
- Pages
- 3165-3169
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC201151
- OpenAlex
- W2106962923
- Cited by
- 231
- References
- 25
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 9 · 2020: 8 · 2019: 6 · 2018: 7 · 2017: 4 · 2016: 12 · 2015: 10 · 2014: 13 · 2013: 13 · 2012: 13
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- voriconazole, triazoles, pharmacokinetics, pharmacodynamics, AUC/MIC ratio, Candida albicans, systemic candidiasis, neutropenic mice, antifungal efficacy, drug-protein binding, elimination half-life, dosing interval, antifungal susceptibility
- MeSH terms
- Administration, Oral, Animals, Antifungal Agents, Candida albicans, Candidiasis, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Kidney, Microbial Sensitivity Tests, Neutropenia, Pyrimidines, Triazoles, Colony Count, Microbial, Fluconazole, Area Under Curve, Drug Resistance, Fungal, Mice, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review